A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

Breast Cancer Research and Treatment

Volumn 137, Issue 2, 2013, Pages 471-482

  Cristofanilli, Massimo ^a,k   Johnston, Stephen R D ^b   Manikhas, Alexey ^c   Gomez, Henry L ^d   Gladkov, Oleg ^e   Shao, Zhimin ^f   Safina, Sufia ^g   Blackwell, Kimberly L ^h   Alvarez, Ricardo H ^a   Rubin, Stephen D ⁱ   Ranganathan, Sulabha ⁱ   Redhu, Suman ⁱ   Trudeau, Maureen E ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c City Oncology Dispensary St Petersburg   (Russian Federation)

^d INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^e Regional Oncological Dispensary   (Russian Federation)

^f FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^g City Oncology Dispensary   (Russian Federation)

^h DUKE CANCER INSTITUTE   (United States)

ⁱ GLAXOSMITHKLINE   (United States)

^j DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^k FOX CHASE CANCER CENTER   (United States)

more..

Author keywords

HER2 positive breast cancer; Inflammatory breast cancer; Lapatinib; Pazopanib

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PAZOPANIB; PLACEBO; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SULFONAMIDE;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THERAPY DELAY; VOMITING; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; INFLAMMATORY BREAST CANCER; METABOLISM; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIARRHEA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; PYRIMIDINES; QUINAZOLINES; RECEPTOR, ERBB-2; SULFONAMIDES; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880603356     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2369-x     Document Type: Article

References (30)

1. Cristofanilli M, Buzdar AU, Hortobagyi GN (2003) Update on the management of inflammatory breast cancer. Oncologist 8:141-148
2. Dirix LY, Van Dam P, Prové A, Vermeulen PB (2006) Inflammatory breast cancer: current understanding. Curr Opin Oncol 18:563-571
3. Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hasson J, Birnbaum D, Jacquemier J, Viens P (2004) Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 202(3):265-273
4. Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F (2008) Defining the molecular biology of inflammatory breast cancer. Semin Oncol 35(1):41-50
5. Parton M, Dowsett M, Ashley S, Hills M, Lowe F, Smith IE (2004) High incidence of HER-2 positivity in inflammatory breast cancer. Breast 13(2):97-103
6. Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377-384
7. Dawood S, Ueno NT, Cristofanilli M (2008) The medical treatment of inflammatory breast cancer. Semin Oncol 35:64-71
8. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN (1995) Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am 4(4):715-734
9. Palangie T, Mosseri V, Mihura J, Campana F, Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Scholl S, Asselain B, Pouillart P (1994) Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 30A(7):921-927
10. Konecny GE, Pegram MD, Venkatesan N et al (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66(3):1630-1639
11. Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N, Johnston S (2009) Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 10(6):581-588
12. Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N (2010) Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 28:3248-3255
13. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY (2004) Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 10:7965-7971
14. Konecny GE, Meng YG, Untch M, Wang H-J, Bauerfeind I, Epstein M, Stieber P, Vernes J-M, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10(5):1706-1716
15. Pegram M, Chan D, Dichmann RA, Tan-Chiu E, Yeon C, Durna L, Lin LS, Slamon D (2006) Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor (VEGF) using trastuzumab (T) and bevacizumab (B) as first-line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 100(Suppl 1):S28 (Abstract 301)
16. Wedam SB, Low JA, Yang SX et al (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24:769-777
17. Sonpavde G, Hutson TE (2007) Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 9(2):115-119
18. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15(12):4220-4227
19. Taylor SK, Chia S, Dent S, Clemons M, Agulnik M, Grenci P, Wang L, Oza AM, Ivy P, Pritchard KI, Leighl NB (2010) A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital Phase II Consortium. Oncologist 15:810-818
20. Slamon D, Gomez HL, Kabbinavar FF, Amit O, Richie M, Pandite L, Goodman V (2008) Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 26(15 suppl):Abstract 1016
21. Slamon DJ, Stemmer SM, Johnston S, Kim S-B, Durante M, Pandite LN, Roychowdhury DF, Goodman VL (2009) Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with first-line HER2 positive advanced or metastatic (adv/met) breast cancer. Cancer Res 69(2 suppl):Abstract 4114
22. Johnston S, Trudeau M, Rubin S, Little S, Heise M, Durante M, Salazar V, Richie M, Cristofanilli M (2010) A novel skin assessment tool for inflammatory breast cancer. Presented at 7th European breast cancer conference; Barcelona, Spain. Abstract 380
23. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9-23
24. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst 97(13):966-975
25. Boussen H, Bouzaiene H, Ben Hassouna J, Dhiab T, Khomsi F, Benna F, Gamoudi A, Mourali N, Hechiche M, Rahal K, Levine PH (2010) Inflammatory breast cancer in Tunisia: epidemiological and clinical trends. Cancer 116(11 suppl):2730-2735
26. Johnston S, Trudeau M, Kaufman B et al (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26:1066-1072
27. Colpaert CG, Vermeulen PB, Benoy I, Soubry A, Van Roy F, van Beest P, Goovaerts G, Dirix LY, Van Dam P, Fox SB, Harris AL, Van Marck EA (2003) Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer 88:718-725
28. Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu Z-F, Merajver SD (2004) WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 6(2):R110-R115
29. Arteaga CL, Mayer IA, O'Neill AM, Swaby RF, Alpaugh RK, Yang XJ, Wagner LI, Meropol NJ, Saphner TJ, Jahanzeb M, Perez EA, Lin NU, Sledge GW (2012) A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2 + MBC): a trial of the Eastern Cooperative Oncology Group (E1105). J Clin Oncol 30(suppl 15):Abstract 605
30. Gianni L, Romieu G, Lichinitser M et al (2011) First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Res 24(suppl 3):Abstract S4-8